An investment to expand U.S. manufacturing capacity for COVID-19 vaccines comes as the administration of President Joe Biden also plans to buy enough of Pfizer’s new COVID-19 pill for about 10 million courses of treatment to be delivered in the next 10 months, paying over $5 billion, according to people familiar with the agreement.